Saint-Paul M T, Brémond A, Rochet Y
Département de Gynécologie, Oncologie gynécologique, Sénologie et Médecine de la Reproduction, Hôpital E.-Herriot, Lyon.
J Gynecol Obstet Biol Reprod (Paris). 1993;22(7):737-42.
To investigate the diagnosis and prognosis aspects of carcinoma of the cervix in a group of young patients less 35 years old, not very clear in literature.
Retrospective and comparative diagnostic and prognostic study. This study is related to the epidemiology and prognosis of such cervical cancer in young women.
Of 449 new patients with carcinoma of cervix FIGO stages IA2-IV treated between 1972-1990 inclusive, 46 patients were aged less than 35 years old.
The frequency is about 10.2%; during the last 20-year period, there was a gradual rise in the proportion of young women with invasive carcinoma of the cervix (7.6% between January 1972 and June 1981, 13.9% between July 1981 and December 1990). There is more frequent incidence of adenocarcinoma in the young women group (19.6% adenocarcinoma < 35 years, 8.2% > 35 years). The overall 5-year survival all stages together is better before 35 years (71% < 35 years, 50% > 35 years), because in women aged less than 35 years, early stages disease (IA2, IB), predominated. Stage for stage, the 5-year survival is a little lower for stage I (78.6% < 35 years, 88.5% > 35 years) and much lower for stage II (45.5% < 35 years, 71% > 35 years). The young age is an independent prognosis factor, predicting early recurrences within 20 months: the relative risk is 3.7.
The young age (less than 35 years), is a worse prognosis factor of carcinoma of the cervix; the treatment is very difficult: heavy (radiotherapy, neoadjuvant chemotherapy), efficient, problem of femininity.
探讨35岁以下年轻宫颈癌患者的诊断及预后情况,这方面在文献中尚不十分明确。
回顾性及对比性诊断与预后研究。本研究涉及年轻女性宫颈癌的流行病学及预后。
在1972年至1990年(含)期间接受治疗的449例国际妇产科联盟(FIGO)分期为IA2-IV期的宫颈癌新患者中,46例年龄小于35岁。
发病率约为10.2%;在过去20年期间,年轻女性浸润性宫颈癌的比例逐渐上升(1972年1月至1981年6月为7.6%,1981年7月至1990年12月为13.9%)。年轻女性组腺癌发病率更高(35岁以下腺癌占19.6%,35岁以上占8.2%)。所有分期的总体5年生存率在35岁之前更高(35岁以下为71%,35岁以上为50%),因为35岁以下女性早期疾病(IA2、IB期)占主导。逐期来看,I期的5年生存率略低(35岁以下为78.6%,35岁以上为88.5%),II期则低得多(35岁以下为45.5%,35岁以上为71%)。年轻是一个独立的预后因素,预示着20个月内早期复发:相对风险为3.7。
年轻(小于35岁)是宫颈癌预后较差的因素;治疗非常困难:强度大(放疗、新辅助化疗)、有效,但存在女性特征方面的问题。